Professional Role and Tenure
Shelby J. Walker served as Senior Vice President, General Counsel, and Corporate Secretary at Korro Bio, Inc. from May 2023 to June 2024. In this capacity, she led Korro Bio’s legal organization, overseeing key functions including Intellectual Property, Corporate Governance, and Compliance. Her role was integral during a critical corporate transition involving the merger of Frequency Therapeutics, Inc. into Korro Bio, marked by Korro’s name change and commencement of Nasdaq trading under symbol KRRO in 2023.
Industry and Company Context
Korro Bio, a biotechnology company specializing in RNA editing technologies, notably developed its proprietary OPERA® platform, which enables precise RNA editing for novel genetic medicines targeting complex and prevalent diseases. The company has recently been active in advancing its research pipeline and securing orphan drug designations, reflecting strategic positioning in rare disease therapeutics.
The company’s leadership group during Shelby Walker’s tenure included CEO Ram Aiyar and CFO Vineet Agarwal, with Walker participating as a legal executive overseeing all governance and intellectual property matters during the integration and expansion phases.
Experience and Background
Shelby Walker has over 20 years of legal experience in the biotechnology sector, with prior positions including Senior Vice President, Intellectual Property at CRISPR Therapeutics and roles at companies such as Ginkgo Bioworks and Dyax. She holds advanced degrees including a J.D. (Juris Doctor) and an M.S., and completed education at The Johns Hopkins University. Her expertise is focused on corporate legal strategy, intellectual property rights, and regulatory compliance within innovative biotech environments.
Involvement in Corporate Transactions and Governance
Walker’s leadership included direct involvement in Korro Bio’s merger transactions. Public filings list her as a key officer responsible for legal due diligence and compliance aspects during the merger closing anticipated in late 2023. She was named explicitly in SEC filings as General Counsel aged 49, further validating her senior status in the company’s leadership team during this period.
Transition and Current Status
In mid-2024, Shelby Walker transitioned from Korro Bio to join Absci as Chief Legal Officer, indicating her continued advancement within the life sciences sector. Her departure from Korro Bio in June 2024 aligns with this career progression.
Summary of Relevant Points for Corporate Context:
- Position: Senior Vice President, General Counsel & Corporate Secretary, Korro Bio, May 2023 – June 2024
- Responsibilities: Legal leadership including Intellectual Property, Corporate Governance, Compliance; oversight during critical merger events
- Industry Expertise: Genetic medicines and RNA editing biotech
- Prior Experience: Senior IP counsel roles at CRISPR Therapeutics, Ginkgo Bioworks
- Education: J.D., M.S.; Johns Hopkins University
- Notable Corporate Activities: Played a key legal role in Korro Bio’s merger with Frequency Therapeutics, company rebranding, and Nasdaq listing
- Current Role: Chief Legal Officer at Absci as of mid-2024
This profile highlights Shelby Walker as a seasoned legal executive with deep sector experience, specifically with strategic transactions and intellectual property leadership pivotal for biopharma companies pioneering cutting-edge RNA editing therapeutics.
